Adult Stem Cells Beneficial In Heart Failure Recovery

Main Category: Cardiovascular / Cardiology
Also Included In: Stem Cell Research
Article Date: 28 Jan 2008 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

A study in the Clinical and Experimental Pharmacology and Physiology published by Wiley-Blackwell shows that administration of adult bone marrow stem cells (BMC) and mesenchymal stems cells (MSC) can aid in the recovery of myocardial infarction (MI) - commonly known as heart attack - and consequently increase survival rates.

The study - "Systemic Delivery of Adult Stem cells Improves Cardiac Function in Spontaneously Hypertensive Rats" - is designed to evaluate the impact of systemic delivery of BMC and MSC on spontaneously hypertensive rats induced with MI.

Lead author, Dr. Nardi says "Our research is the first to show this type of stem cell activity in a physiological model of MI, as we used spontaneously hypertensive rats which closely represent the disease in humans."

The treatment with stem cells resulted in statistically different mortality rates- 0% for rats treated with BSC, 17% for rats treated with MSC and 45% for non-treated rats. Rats that were treated also showed significant recovery of heart function and capacity.

"Results suggest that injected BMC can bring about therapeutic effects, especially in tissue regeneration. It speeds up the adaptive remodeling of the heart and consequently increases survival rates", says Dr. Nardi.

Although many studies have shown the potential beneficial effects of stem cell therapies in treatment for heart failure, delivery methods are still under investigation.

Author of the editorial commentary in this issue, John Haynes says "In this issue, Nardi and co-workers have demonstrated significant improvement in cardiac function and reduction in mortality of the rats following the administration of BSC bringing us closer to unraveling the mystery of the stem cell."

About Clinical and Experimental Pharmacology and Physiology

Clinical and Experimental Pharmacology and Physiology provides a medium for the rapid publication of original research papers, short communications, rapid communications and theoretical articles (hypotheses) on the results of clinical and experimental work in pharmacology and physiology. Invited review articles are published occasionally.

Wiley-Blackwell

Wiley-Blackwell was formed in February 2007 as a result of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wiley's Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,400 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit http://www.blackwellpublishing.com or http://interscience.wiley.com.

About Wiley

Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for 200 years, helping people around the world meet their needs and fulfill their aspirations. Since 1901, Wiley and its acquired companies have published the works of more than 350 Nobel laureates in all categories: Literature, Economics, Physiology/Medicine, Chemistry and Peace.

Our core businesses include scientific, technical, medical and scholarly journals, encyclopedias, books, and online products and services; professional/trade publishes books, subscription products, training materials, and online applications and websites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.

John Wiley & Sons, Inc.